Skip to main content

Table 1 Participant demographics

From: Impact of cerebral blood flow and amyloid load on SUVR bias

  [18F]flutemetamol [18F]florbetaben
All (N = 90) Aβ-negative (N = 71) Aβ-positive (N = 19) All (N = 31) Aβ-negative (N = 19) Aβ-positive (N = 12)
Age 67.2 ± 6.3 66.2 ± 6.3** 70.7 ± 4.7 67.3 ± 7.4 66.0 ± 6.7 69.5 ± 8.2
Females % 54.4 57.7 42.1 67.7 73.7 58.3
MMSE 28.9 ± 1.4 29.2 ± 1.1 28.2 ± 2.1 29.1 ± 1.3 29.4 ± 0.8 28.7 ± 1.8
APOE-ε4 + % 41.6 34.3* 68.4 35.5 15.8* 66.7
SUVR 1.51 ± 0.3 1.41 ± 0.1** 1.86 ± 0.3 1.48 ± 0.2 1.36 ± 0.1** 1.66 ± 0.3
DVR 1.23 ± 0.1 1.18 ± 0.1** 1.41 ± 0.2 1.26 ± 0.2 1.18 ± 0.1** 1.40 ± 0.2
R1 1.00 ± 0.1 1.00 ± 0.1 0.97 ± 0.1 0.96 ± 0.2 0.96 ± 0.1 0.95 ± 0.1
Centre A,B,C,D A,B,C,D A,B,C A A A
Inj. dose (MBq) 186.2 ± 10.4 188.8 ± 10.1 184.0 ± 7.7 282.9 ± 19.7 284.4 ± 17.9 280.5 ± 22.9
  1. Values depicted as mean ± SD, MMSE = mini-mental state examination, Inj. dose = Net injected dose *p < 0.05, **p < 0.01, compared with the Aβ-positive group. A = Amsterdam UMC, B = BBRC, C = UNIGE, D = Edinburgh